Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - AT&S, AMAG, Marinomed (17/09/2025)

21.09.2025

AT&S: The Deputy CEO and EVP of the Business Unit Electronics Solutions, Peter Schneider, will step down from the Management Board of AT&S AG on September 30, 2025, in order to pursue new professional challenges. With the departure of Peter Schneider, CEO Michael Mertin will assume interim responsibility for the management of the Business Unit Electronics Solutions.
AT&S: weekly performance: 12.94%

AMAG: At its meeting on September 17, 2025, the Supervisory Board of AMAG Austria Metall AG resolved to extend the contract of Chief Sales Officer Victor Breguncci, MBA, until May 31, 2029. The Brazil native has been a member of AMAG’s Management Board since June 2019 and is responsible for Sales, Strategic Sales Development, Supply Chain Management, as well as Market Monitoring and Development. “In light of the current challenges facing the European aluminium industry, I am especially grateful for the trust placed in me. I look forward to continuing to take on responsibility together with my dedicated team and fellow board members. Our goal is to lead AMAG into the future as a reliable partner for high-quality aluminium solutions,” says Victor Breguncci. Since January 1, 2024, the AMAG Management Board has consisted of CEO and COO Dr. Helmut Kaufmann, CFO Claudia Trampitsch, and CSO Victor Breguncci, MBA.
Amag: weekly performance: -0.41%

Marinomed: Marinomed Biotech AG increased its sales revenue from €2.4 million to €7.2 million in the first half of the year. This includes initial payments of €5 million from the sale of the Carragelose business. Additional revenues came from the remaining Carragelose business, the service agreement with Unither, and Solv4U. Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2 million), significantly influenced by other operating income of EUR 19.3 million, which includes a restructuring gain of EUR 18.9 million. Cash flow from operating activities was slightly negative at EUR –0.2 million. Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5 million, compared to EUR 0.9 million in the previous year. 
Marinomed Biotech: weekly performance: -3.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/09/2025)


Partners









latest 21st Austria

21st Austria weekly - AT&S, AMAG, Marinomed (17/09/2025)


21.09.2025, 2220 Zeichen



AT&S: The Deputy CEO and EVP of the Business Unit Electronics Solutions, Peter Schneider, will step down from the Management Board of AT&S AG on September 30, 2025, in order to pursue new professional challenges. With the departure of Peter Schneider, CEO Michael Mertin will assume interim responsibility for the management of the Business Unit Electronics Solutions.
AT&S: weekly performance: 12.94%

AMAG: At its meeting on September 17, 2025, the Supervisory Board of AMAG Austria Metall AG resolved to extend the contract of Chief Sales Officer Victor Breguncci, MBA, until May 31, 2029. The Brazil native has been a member of AMAG’s Management Board since June 2019 and is responsible for Sales, Strategic Sales Development, Supply Chain Management, as well as Market Monitoring and Development. “In light of the current challenges facing the European aluminium industry, I am especially grateful for the trust placed in me. I look forward to continuing to take on responsibility together with my dedicated team and fellow board members. Our goal is to lead AMAG into the future as a reliable partner for high-quality aluminium solutions,” says Victor Breguncci. Since January 1, 2024, the AMAG Management Board has consisted of CEO and COO Dr. Helmut Kaufmann, CFO Claudia Trampitsch, and CSO Victor Breguncci, MBA.
Amag: weekly performance: -0.41%

Marinomed: Marinomed Biotech AG increased its sales revenue from €2.4 million to €7.2 million in the first half of the year. This includes initial payments of €5 million from the sale of the Carragelose business. Additional revenues came from the remaining Carragelose business, the service agreement with Unither, and Solv4U. Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2 million), significantly influenced by other operating income of EUR 19.3 million, which includes a restructuring gain of EUR 18.9 million. Cash flow from operating activities was slightly negative at EUR –0.2 million. Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5 million, compared to EUR 0.9 million in the previous year. 
Marinomed Biotech: weekly performance: -3.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/09/2025)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1052: ATX TR nach Rekord 50 heute etwas leichter, gute Phase für RBI, VIG und Uniqa, Opening Bell Petra Heindl




 

Bildnachweis

Aktien auf dem Radar:VIG, UBM, RBI, Pierer Mobility, OMV, RHI Magnesita, DO&CO, Kapsch TrafficCom, FACC, AT&S, CA Immo, Lenzing, Austriacard Holdings AG, Frequentis, Gurktaler AG Stamm, Oberbank AG Stamm, Amag, Flughafen Wien, Österreichische Post, Strabag, Telekom Austria, Deutsche Bank, BMW, Porsche Automobil Holding, Fresenius Medical Care, Deutsche Boerse, Vonovia SE, Allianz, Bayer, Beiersdorf, Rheinmetall.


Random Partner

Hypo Oberösterreich
Sicherheit, Nachhaltigkeit und Kundenorientierung sind im Bankgeschäft Grundvoraussetzungen für den geschäftlichen Erfolg. Die HYPO Oberösterreich ist sicherer Partner für mehr als 100.000 Kunden und Kundinnen. Die Bank steht zu 50,57 Prozent im Eigentum des Landes Oberösterreich. 48,59 Prozent der Aktien hält die HYPO Holding GmbH. An der HYPO Holding GmbH sind die Raiffeisenlandesbank Oberösterreich AG, die Oberösterreichische Versicherung AG sowie die Generali AG beteiligt.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten